Treatment-Free Remission in Chronic Myeloid Leukemia in Low- and Middle-Income Countries

Treatment-Free Remission in Chronic Myeloid Leukemia in Low- and Middle-Income Countries

We’re pleased to share that the New England Journal of Medicine has published our “Letter to the Editor” on treatment-free remission for chronic myeloid leukemia in low- and middle-income countries!

It was written in collaboration with Dr. Jerry Radich from the Fred Hutchinson Cancer Research Center and partner physicians from Armenia, the Dominican Republic, El Salvador, Ethiopia, Honduras, India, Kenya, and Paraguay.

Read More

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • Interviews with VJHemOnc

    Interviews with VJHemOnc

    At the 13th Annual SOHO Meeting in Houston (Sept 3–6, 2025), Andrielle Yost, Associate Director of Public Sector Engagement at The Max Foundation, discusses the work the organization is doing to improve access to chronic lymphocytic leukemia (CLL) treatment for patients in low- and middle-income countries (LMICs). Watch the interview here. You can also watch….

  • The Max Foundation Announces Agreement with Lilly to Provide Access to Verzenio® (abemaciclib) for the Treatment of Advanced Breast Cancer in Kenya

    The Max Foundation Announces Agreement with Lilly to Provide Access to Verzenio® (abemaciclib) for the Treatment of Advanced Breast Cancer in Kenya

    Agreement to provide Verzenio® (abemaciclib) free of charge to patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) Lilly joins ongoing effort of Humanitarian Partnership for Access to Critical Treatment (Humanitarian PACT) to eliminate healthcare disparities for patients living with advanced breast cancer in low- and middle-income countries….

  • Inaugural ERSAP Prize Awarded to Pat Garcia-Gonzalez

    Estoril, Portugal– In recognition of her personal contribution and role in leading The Max Foundation in increasing access to treatment, care, and support for people living with cancer around the world, Max CEO, Pat Garcia-Gonzalez is the first recipient of the International Chronic Myeloid Leukemia (CML) Foundation’s ERSAP Prize. The International CML Foundation awarded our….